China Resources Pharmaceutical (03320.HK): Net profit attributable to the parent company of 4.046 billion yuan in 2025, a year-on-year increase of 20.7%

Guotong Hui March 25 — China Resources Pharmaceutical (03320.HK) announced that for the year ending December 31, 2025, the group achieved total revenue of RMB 269.574 billion, a year-on-year increase of 4.6%. In 2025, the revenue share of the three main business segments—pharmaceutical manufacturing, pharmaceutical distribution, and retail pharmacy—was 16.8%, 78.7%, and 4.5%, respectively. During the reporting period, the group realized a gross profit of RMB 44.508 billion, up 9.4% year-on-year. The overall gross profit margin was 16.5%, an increase of 0.7 percentage points compared to 2024.

During the reporting period, the group achieved a net profit of RMB 9.653 billion, a steady increase of 14.9% year-on-year; attributable net profit to shareholders was RMB 4.046 billion, a significant increase of 20.7%. Basic earnings per share for the period were RMB 0.64, and the board declared a final dividend of RMB 0.122 per share (compared to RMB 0.052 for the 2024 final dividend).

In terms of external growth during the reporting period, the group completed multiple acquisitions in biopharmaceuticals, traditional Chinese medicine, and chemical drugs, introduced several high-quality products, established industrial development funds, and further diversified investment methods. In technological innovation, the group promoted new product launches, strengthened external collaborations, advanced several innovation consortia, and optimized product portfolios and business structures. In operational management, the group focused on building an excellent operational system, continuously promoted cost reduction and efficiency improvement, and enhanced digital intelligence capabilities, earning multiple industry honors. In supply chain development, the group strengthened upstream and downstream coordination and control, continuously improved supply chain resilience and overall competitiveness. In international expansion, the group achieved registration and sales in multiple products across various countries, further enhancing the influence of traditional Chinese medicine culture.